Low-Dose Rapamycin Weekly vs Daily: What the Trials Actually Compared

Weekly dosing has become the default assumption in longevity circles, repeated so often that it reads as settled. It is worth asking where that came from, because the one human trial that compared the two schedules head to head did not pick weekly.

That is not an argument for daily dosing. It is an argument that the question is open, and that the confidence with which "weekly" gets stated online is not coming from the evidence. Three bodies of work bear on this — a six-week immune study in older adults, a year-long placebo-controlled trial of weekly dosing, and a mouse study that ran both schedules to the end of life — and they disagree with each other in ways that are more interesting than the consensus.

The two schedules are different drugs, not different frequencies

Rapamycin inhibits mTORC1. The whole premise of intermittent dosing is that mTORC1 suppression and mTORC2 suppression come apart in time: short, spaced exposure is thought to hit mTORC1 while letting mTORC2 — where the metabolic side effects are believed to originate — recover between doses.

If that premise holds, a weekly protocol and a daily protocol delivering the same weekly total are not the same intervention at different frequencies. They are two different interventions, and comparing them on milligrams alone misses the mechanism being tested. Most online dose comparisons do exactly that.

It is worth being precise about what is approved here. Rapamycin, as Rapamune, is approved for prophylaxis of organ rejection in kidney transplant recipients and for lymphangioleiomyomatosis. The labelled regimen is once daily, with an initial 2 mg/day adjusted to trough concentrations [6]. Every longevity use is off-label, and no regulator has reviewed a weekly protocol for any purpose. There is no approved schedule to appeal to, which is part of why the argument is as unanchored as it is.

The only human head-to-head favoured daily

In 2014, a Novartis-led team gave healthy adults aged 65 and over the rapamycin analogue everolimus for six weeks, then an influenza vaccine two weeks after stopping, and measured the antibody response [3]. The arms are the point: 0.5 mg daily, 5 mg weekly, and 20 mg weekly.

The lower-dose arms improved vaccine response by roughly 20%, with at least a 1.2-fold increase in haemagglutinin-inhibition titres for two of the three vaccine strains. The response also broadened, with seroconversion to strains not in the vaccine. Adverse events did not rise at the lower doses.

The 20 mg weekly arm — the one producing the most complete S6K suppression — did not do better. A later trial protocol from the same research line states it directly: 0.5 mg daily outperformed everolimus 20 mg once weekly for improving influenza vaccination responses in older adults [4].

That is the only head-to-head schedule comparison in humans this field has, and it points toward low-dose daily rather than high-dose weekly. Three caveats belong with it, and none of them make it go away. It used everolimus, not rapamycin. It ran six weeks, not years. And the authors were Novartis employees with equity in the company that developed the drug [3] — a conflict the paper discloses, and one worth weighing, though it cuts against the finding being a marketing artifact: Novartis had no weekly product to protect.

The follow-on programme is also instructive, and it is where the "intermittent is better" line actually originates. The same group ran RTB101, a related mTOR inhibitor, through phase 2b and phase 3 in more than 1,500 adults aged 65 and over [4]. The phase 2b design is the relevant part: it compared once-daily RTB101 against twice-daily RTB101 against RTB101 combined with everolimus — a dose-intensity comparison rather than a schedule comparison, which is worth noting before the conclusion gets borrowed. Pooled analysis showed once-daily RTB101 reduced laboratory-confirmed respiratory infections — 34 of 176 versus 50 of 180 on placebo — but the combination arm missed statistical significance in the first prespecified analysis, the programme missed its primary endpoint, and the drug did not proceed. One published commentary went further, noting that the trial increased rather than decreased respiratory illness risk on its primary measure, which is the opposite of what you would predict for an immunosuppressant and which nobody has fully explained. The authors' own reading is that intermittent mTOR inhibition might be more effective than persistent inhibition. That is a hypothesis stated by the researchers, not a result they demonstrated, and it has been quoted downstream as though it were the latter.

PEARL is the best weekly data we have, and it missed its primary endpoint

PEARL is the trial most often cited for weekly rapamycin, and it deserves a careful read rather than a headline [1][2]. It was a 48-week randomised, double-blind, placebo-controlled trial in healthy adults aged 50 to 85. Of 125 who started, 114 finished: 40 on 5 mg weekly, 35 on 10 mg weekly, 39 on placebo.

The primary endpoint was visceral adipose tissue, and it did not move (p = 0.942) [1]. Everything else in the paper is secondary.

On safety, the result is genuinely reassuring within its limits. Serious adverse events ran one, two and three across the 10 mg, 5 mg and placebo groups — placebo had the most. Non-severe events were effectively identical at 117, 116 and 122. Gastrointestinal symptoms were somewhat more common on rapamycin (eight and seven versus four). One anaemia case in the 5 mg group resolved after transfusion and did not recur. Various blood markers shifted but stayed in normal range: red blood cells rose in the 5 mg group, blood urea nitrogen rose in men at 10 mg, HbA1c rose slightly in men at 5 mg, and CO2 and calcium fell at 10 mg [1]. None of those crossed a clinical threshold in this cohort, which is the reassuring part. The less reassuring part is that they moved in different directions at different doses in different sexes, in a study of 114 people — a pattern that is as consistent with noise as with a dose-response.

The efficacy findings are where care is needed. The headline is lean tissue mass in women on 10 mg weekly — a mean difference of 6.194 versus placebo at 48 weeks (95% CI 0.877 to 11.511, p = 0.018) [1]. That is a real result, and it is also resting on eight women. A confidence interval running from 0.88 to 11.5 is telling you how little the study could pin down. Pain scores improved in women, though the paper's own results section and abstract attribute that differently, and the table does not break it out by dose. WOMAC osteoarthritis scores did not change in any group. Bone mineral content did not change; men on 10 mg showed a trend against 5 mg at p = 0.057. Bone mineral density was reduced in the 5 mg group (OR 0.24, p = 0.04), which the authors report as significant and which does not fit a simple dose-response story.

Then the limitation that reframes the dosing conversation entirely: the compounded rapamycin PEARL used reached about one-third the blood concentration of commercial rapamycin at 24 hours. The trial was paused while this was investigated, and the authors state that equivalent effective doses for compounded forms run roughly 66% lower than the label figure [1]. So "10 mg weekly" in PEARL is not 10 mg weekly as most readers would understand it, and anyone copying that number from a commercial pharmacy is not running the protocol they think they are.

The authors are employees and shareholders of AgelessRx, disclosed in the paper [1]. As with the Novartis work, that is context rather than disqualification — but a trial whose primary endpoint failed and whose positive findings sit in an eight-person subgroup is thin ground for a confident protocol.

Anyone who does pursue either schedule needs baseline and follow-up bloodwork, and the panel is ordinary rather than exotic — lipids, glucose, HbA1c, a complete blood count. You can compare blood-work providers instead of guessing at what to request, and at-home panels through Everlywell cover most of it. For anything requiring a prescribing clinician in the loop, PeterMD and Strut Health are the practical options. Our diagnostics and testing hub covers which markers are worth tracking over time.

In mice, the schedules split by outcome rather than producing a winner

The cleanest comparison exists in mice, because you can run both arms to the end of life. Baghdadi and colleagues did exactly that, publishing in Molecular Metabolism in 2024 [5]. From six months of age, hybrid mice received either continuous 42 mg/kg rapamycin in food, or alternating weeks of rapamycin food and control food.

The results refuse to pick a side:

The authors' conclusion is worth quoting in substance: intermittent dosing prolongs lifespan and reduces some side effects of chronic treatment, but chronic treatment is more beneficial to healthspan [5].

That is a trade, not a victory. Intermittent dosing buys you a better metabolic side-effect profile and gives up some of the healthspan benefit. If you had told a longevity forum in advance that the continuous arm would win on inflammation and age-related pathology, it would have been treated as a surprising result. It is the actual result.

The caution attached to all of it: these are mice, on 42 mg/kg in chow, which is not a human protocol at any schedule. The mouse data is the only place both arms have been run to death, and that is exactly why it is useful — and exactly why it cannot be translated into a milligram figure for a person.

It is also worth noticing what the intermittent arm in that study actually was. Alternating weeks of drug and control food is a far longer cycle than the once-weekly human protocols it gets cited to support. A mouse on a week-on, week-off schedule spends half its life at continuous exposure. Whatever that experiment demonstrates about pulsed mTORC1 inhibition, it is not a direct test of taking 5 mg every Sunday, and the gap between the two is routinely elided.

Where the weekly consensus actually came from

Put the three sources together and the picture is not the one circulating.

The strongest mechanistic argument for weekly dosing — mTORC1 without mTORC2 — is a theory with real support. The strongest empirical claim for it, the Mannick group's suggestion that intermittent inhibition may beat persistent inhibition, is their interpretation of a trial that missed its primary endpoint [4]. The only direct human comparison favoured low-dose daily [3]. And the lifetime mouse comparison gave the intermittent arm a better metabolic profile while continuous won on inflammation and pathology [5].

What happened, as best I can reconstruct it, is that a reasonable mechanistic hypothesis and a researcher's cautiously worded suggestion were compressed into a protocol, and the protocol then got repeated until it sounded like a finding. That is a very common failure mode in this field, and it is worth naming when the underlying question is still genuinely open.

None of this means weekly dosing is wrong. The safety data from PEARL is real, 48 weeks is a meaningful duration, and the glucose-tolerance advantage in the mouse work is a legitimate reason to prefer intermittent exposure. The honest position is narrower than either camp's: weekly is a defensible choice with a better-characterised safety profile in humans, daily has the only head-to-head win on a functional endpoint, and nobody has run the trial that would settle it.

If you are reading protocol advice that does not mention that PEARL's primary endpoint failed, or that its rapamycin was a third as bioavailable as the commercial product, you are reading marketing. The same test applies to anything in this category — see what leading longevity researchers actually recommend and the anti-aging strategies with real evidence behind them for the same filter applied more broadly, and which tests are worth running annually for the monitoring side.

Frequently asked questions

Is rapamycin approved for longevity?

No. It is approved for prophylaxis of organ rejection in kidney transplant recipients and for lymphangioleiomyomatosis, with a once-daily labelled regimen starting at 2 mg/day and adjusted to trough levels [6]. Every longevity application is off-label, and no regulator has evaluated a weekly protocol for any indication.

Does weekly dosing actually reduce side effects?

In mice, partly — intermittent dosing relieved some of the glucose intolerance that continuous treatment induced [5]. In humans, PEARL found weekly dosing broadly comparable to placebo on adverse events over 48 weeks, with somewhat more gastrointestinal symptoms [1]. What has not been shown in humans is that weekly produces fewer side effects than daily, because no human trial has compared the two on that question.

Has any trial shown rapamycin extends human lifespan?

No, and none is running. Human endpoints in this area are surrogate markers — immune response, body composition, biological-age estimates. PEARL's primary endpoint was visceral adipose tissue, and it did not change [1]. A lifespan trial in humans would take decades and has not been attempted.

Why do PEARL's doses not match what a pharmacy would dispense?

Because the compounded rapamycin PEARL used reached roughly one-third the blood concentration of commercial rapamycin at 24 hours, and the authors state that equivalent effective doses for compounded forms are about 66% lower than listed [1]. Copying "10 mg weekly" from the trial using a commercial product is not reproducing the protocol.

What should be monitored on either schedule?

Lipids, fasting glucose and HbA1c, a complete blood count, and kidney and liver markers, taken at baseline and repeated on follow-up. PEARL saw shifts in red blood cells, BUN, HbA1c, CO2 and calcium across its arms, all within normal range but all worth watching in an individual [1]. The anaemia case in that trial is the specific reason a CBC belongs in the panel.

Sources

• [1] Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results, Aging (Albany NY), 2025
• [2] NCT04488601 — Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL)
• [3] Mannick et al., mTOR inhibition improves immune function in the elderly, Science Translational Medicine, 2014
• [4] Mannick et al., Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials, Lancet Healthy Longevity, 2021
• [5] Baghdadi et al., Intermittent rapamycin feeding recapitulates some effects of continuous treatment while maintaining lifespan extension, Molecular Metabolism, 2024
• [6] Rapamune (sirolimus) US prescribing information, FDA